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Abstract 
IMRT (Intensity Modulated Radiation Therapy) is the latest radiotherapy technique 
for high dose treatment of complex shaped tumors or neoplasm close to sensitive 
organs at risk. VMAT (Volumetric Modulated Arc Therapy) is next generation arc 
therapy technique which performs uninterrupted arc(s) around the patient, 
dramatically speeding treatment delivery and reducing treatment times to those 
required for “conventional” radiation therapy. Beam modulation is obtained by 
continuous changes in collimator morphology on the basis of target shape and in 
dose rate during gantry rotation around the patient. Since November 2010, in our 
institution, 257 patients were treated with VMAT. Plan evaluation was performed 
using Homogeneity and Conformity Index and a phantom (Delta 4) to control 
correspondence between calculated and delivered dose. In our experience VMAT 
provides to dose distributions comparable with most of other IMRT systems, but 
with a dramatic shortening of delivery time with considerable advantages in terms 
of treatment reproducibility (reduction of intrafraction movement of the patient), 
radioprotection and organization of LINAC spaces.  
 
 
 
 
Introduction 
IMRT represents the most recent evolution of 
radiation technologies. It allows 
improvement of therapeutic index both 
arising tumor control probability, due to dose 
increment to target, and reducing side 
effects.  
Dose modulation and escalation can be 
achieved by an increment of beam number, a 
gantry rotation (arc therapy), multileaf 
collimator (MLC) shape dynamic modification 
or dose rate modulation (fig 1). 
The main limit of IMRT treatments is 
represented by long fraction delivery time  
 
 
and high number of monitor units per 
fraction. Furthermore, using a multiple field-
IMRT or Serial Tomotherapy, radiation  
linkage and scattering is not trascurable, 
probably affecting effective delivered dose. 
The aim of this paper is to describe a dynamic 
IMRT technology, VMAT® (Volumetric 
Modulated Arc Therapy), in use in Radiation 
Oncology Unit of “Vito Fazzi” Hospital (Lecce) 
since November 2010. In particular, we will 
describe VMAT application in the care of 
Head and Neck, Pelvic primitive neoplasm 
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and brain metastasis and its utility in overcoming IMRT limits.  
 
 
 
 
 
Materials and methods 
VMAT delivers radiation by rotating the 
gantry of linac around the patient  through  
one or more arcs with radiation continuously 
on. As it do so, a number of parameters can 
be varied. These include: 
 MLC aperture shape 
 the fluence output rate (dose rate) 
 the gantry rotation speed 
 the MLC orientation [1] 
Treatment is performed by rotating the 
gantry over a single or dual arc(s), with MLC 
set and shaped to cover target. This entails 
rapid execution of a sequence of control 
points each defining multileaf collimator 
(MLC) shape, MLC segment dose, and a 
gantry-angle window across which each 
shape sweeps dynamically (Fig 2).  
The genesis of the method was with intensity 
modulated arc therapy (IMAT) from Cedric Yu 
back in 1995, but VMAT adds the variability 
of parameters above mentioned, thus 
reducing the need to use as many arcs as 
there are maximum number of field 
components (fig 1). 
VMAT can deliver highly conformal dose 
distributions similar to those created by 
other forms of intensity-modulated radiation 
therapy (IMRT), including the multiple-static 
field MLC technique, the dynamic MLC 
(DMLC) technique, static and helical 
tomotherapy, the CyberKnife, scannedbeam 
therapy and so on (hereafter referred to as 
“conventional” IMRT). 
Provided that the gantry speed can be varied 
continuously, it does not require a 
continuous variation of fluence-output rate 
to obtain a continuous variability of fluence 
output rate per degree. 
The minimum fluence-output rate and the 
maximum gantry speed determine the 
constraining minimum fluence output rate 
per degree. Where there is a maximum 
fluence-output rate and minimum gantry 
speed, there will be a constraining maximum 
fluence output rate per degree.  
 
 
 
 
 
Since November 2010, in our institution, 257 
patients were treated with VMAT. Schematic 
representation of patients who underwent to 
this therapy and their disease is shown in 
table 1. 
In every patient, a 3 mm thickness-CT scan of 
tumor site was acquired in treatment 
position. On every slice were defined one or 
more PTV(s) (planned target volume) and the 
organs at risk of side effects development 
(OARs). Treatment planning was calculated 
on Oncentra Masterplan®, using a specific 
inverse planning system. Treatment plans 
were evaluated using isodose distribution, 
DVH (dose-volume histogram) and a quality 
index (CI) : 
75 
 
Conformity Index (CI): R I R I
R I
T V T V
T V V
;  
TVRI : Target volume covered by the reference 
isodose; TV: Target volume; VRI : Volume of 
the reference isodose) 
 
 
In every treatment plan, target volumes 
called PTV were delined and a potential 
curative dose is prescribed. To avoid or to 
reduce incidence of side effects, constraints 
to OARs were individuated. These constraints 
corresponds to doses that produce toxicity in 
5% of cases in 5 years (table 2) (2-10). 
Target coverage and OARs doses are 
evaluated on DVH. 
 
 
 
Head and Neck 
In Head and Neck cancer treatment, three 
PTVs with three different  dose levels were 
defined as below: 
- PTV1: primary and positive nodes. 
Prescription dose 69.9 Gy in 2.33 Gy-daily 
fractions 
- PTV2: nodes at high risk of subclinical 
involvement. Prescription dose 60 Gy in 2 
Gy-daily fractions 
- PTV3: nodes at low risk of subclinical 
involvement. Prescription dose 54 Gy in 
1.8 Gy-daily fractions 
Total fractions number is 30. 
Organs at risk to develop toxicity were: 
- spine 
- brainstem 
- parotid glands 
- optic and ocular structures (eyes, 
lenses, optic nerves, optic 
chiasma) 
Contouring of PTVs and OARs is shown in fig. 
3.  
 
 
 
Pelvic Malignancies 
Prostate cancer 
In Prostate Cancer, treatment volumes were 
often represented by prostate and seminal 
vescicles (fig 4A).  
Prescription dose were 78.4 Gy  in 35 
fractions for prostate (fraction dose: 2.24 
Gy)and 66.5 Gy for seminal vescicles (fraction 
dose: 1.9 Gy). 
In case of high risk of subvclinical 
involvement, prophylactic irradiation of 
pelvic nodes was indicated. In this case, 
target volumes and prescription doses were 
PTV1 (prostate, seminal vescicles and 
macroscopically involved nodes) treated with 
70 Gy and PTV2 (negative pelvic nodes) 
treated with 50-56 Gy in 28 fractions 
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(fraction doses 2.5 and 1.8-2 Gy respectively) 
(fig 4B).  
Ginecologic cancers 
PTVs (fig. 5) and prescription doses were: 
 Tumor side and involved Nodes: 66 Gy 30-
33 fraction of 2.33-2 Gy 
 Rest of uterus (when it is surely not 
involved; PTV2): 60 Gy in 30-33 fractions 
of 2-1.8 Gy 
 Negative nodes (PTV3): 54-56 Gy in 30-33 
fractions of 1.8-1.7 Gy 
OARs were small bowel, rectum, bladder. 
 
 
Brain metastasis 
IMRT with VMAT was indicated in patients 
with 1-3 brain metastases (maximum 
diameter of largest metastasis ≤ 3 cm). A GTV 
(Gross Tumor Volume) including the lesions 
macroscopically visible was delined on CT 
scan. PTV1 derived from GTV with 3mm 
margin. PTV2 included the whole brain. 
Prescription doses were: 40Gy in 4Gy-daily 
fraction for PTV1 > 2cm and 50Gy in 5Gy-
daily fractions for PTV1 <2cm. 
 
 
 
Total dose for whole brain was 30Gy in 3Gy-
daily fractions. 
OARs were:  
 Ocular and optic structures 
 Auricular and acoustic structures 
 Brainstem 
Results 
In every treatment plan, high dose 
conformation around target was required 
before final approval. In particular, all plans 
had Conformity Index  included between 0 
and 1, that means in line with IMRT protocols 
or with only a minor violation. 
In Head and Neck cancer, spine sparing was 
performed in all plans and parotid sparing 
was achievable in 90% of cases. 
In all plan 95% of prescribed dose covered 
95% of target volume (fig. 6A). To obtain 
acceptable dosimetric result and OARs 
sparing, it was necessary to program 
treatment usin two 340-degree arcs. 
Fraction duration was 12-20 minutes. 
In Pelvic Malignancies bladder and rectum 
sparing was achievable in all treatment plans 
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(fig. 6 B, C, D). In prostate cancer, when nodal 
irradiation was not required, acceptable 
dosimetric result could be achieved using 
only an arc. In this case, treatment duration 
was 5-7 minutes. To obtain an adequate 
coverage of 
nodal pelvic chains,  in prostate and 
gynecologic neoplasm, two 340° arcs are 
required, with a fraction time of 12-15 
minutes. 
Also in Brain Metastasis treatment, high 
dose and conformation around target and 
OARs sparing can be easily achieved using a 
double arc VMAT plan. Treatment duration 
was 12-15 minutes. 
Discussion  and Conclusions 
VMAT is characterized by a series of technical 
advantages listed below: 
 Fast Seamless Field Delivery 
 Continuously Variable Dose-Rate 
 Variable Gantry Speed 
 Optimized Patient Positioning (couch 
movement in the three dimensions) 
 Optimized Collimator Angle 
 Seamless Field Delivery Interdigitation  
 
These advantages provide to an easy delivery 
of intensity modulated radiation treatment 
and, in particular, simoultaneous delivery of 
different dose levels to different target 
volumes (SIB: simultaneous integrated 
boost). 
SiB obtained with a single treatment plan, 
allows reduction in overall treatment time 
with consequent reduction in tumor 
repopulation probability. Moreover, using a 
daily fraction higher than 2 Gy (daily-2 Gy = 
Conventional Fractionation= CF), biological 
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equivalent dose (BED) on target volume is 
higher than the nominal dose , with an 
improvement in tumor control probability. 
The calculation of BED is effectuated using 
the formula below: 
 
                         BED= D   
 
Where: D= nominal prescribed dose; /β= 
ratio specific for different tissue, describing 
tissue sensibility to radiation; d= fraction 
dose; 2= dose fraction in CF. 
Result of VMAT optimization may, however, 
depend on number of arcs, maximal delivery 
time and gantry angle spacing between 
subsequent control points. Some studies 
demonstrate that a single arc can achieve 
dosimetry comparable with IMRT for 
prostate cancer, but not for more 
complicated PTV, so in most cases a double 
arc treatment is necessary to achieve 
acceptable dosimetric results, affecting the 
duration of fraction delivery. 
Although in a study single arc-VMAT seems  
to produce in Head and Neck cancer similar 
dosimetric results with less Monitor Unit 
than Step and Shoot IMRT (11), most series 
suggest that dual arc provide to an higher 
plan quality. Using dual arc increase 
calculation time. However, both single and 
dual arc reduce delivery time compared with 
other IMRT. Optimization usin larger spacing 
between control points can reduce 
calculation time. In fact, dosimetric result are 
comparable using an interval of 6° or 4° or 2° 
(12) 
In treatment of brain metastasis with SIB and 
high dose fraction, with a theoretical arising 
of tumor control probability, there is an 
increased probability of developing side 
effects like cognitive functions. A study 
demonstrate that this effect is more evident 
in questionnaire of patients treated with SIB-
higher fraction doses, without a worsening in 
Quality of Life (13).  
VMAT is a quite rapid IMRT technique. It is 
more accurate and efficient in delivery than 
the other IMRT, because of a drastic (8.5%) 
reduction in Monitor Unit (11). This data 
suggest that VMAT could be the ideal 
technique to treat also volume fast modifying 
(e.g. bladder). 
In our experience, VMAT is an efficient IMRT 
technology, able to join  excellent dosimetric 
results with rapid delivery. Unfortunately, 
the calculation time is too long and this  
creates difficulties in Radiotherapy and 
Physics Units organization since it is  
necessary that part of the staff has to be 
exclusively dedicated to the optimization of 
these treatment plans. 
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